Our services

ADC Review
is made possible by:




PEER-REVIEWED ARTICLES

CytomX Therapeutics Acquires Technologies Developed by Agensys

Clinical-stage and oncology-focused biopharmaceutical company CytomX Therapeutics, pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, has acquired drug-conjugate linker-toxin and CD3-based bispecific technologies from Agensys, an affiliate of Astellas Pharma.

Under the terms of the agreement, CytomX will pay Astellas a one-time, up-front payment.

“The clinical progress we reported throughout 2018 provided initial proof of concept for our Probody therapeutic platform. This transaction with Astellas provides us with novel payloads and CD3 binding moieties for our next wave of potent anti-cancer agents that leverage our technology, including Probody drug conjugates and Probody T-cell engaging bispecifics,” explained W. Michael Kavanaugh, M.D. chief scientific officer and head of research and non-clinical development at CytomX.

Pipeline
Probody therapeutics developed by CytomX are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues.

The company and its partners have four programs in the clinic, includes cancer immunotherapies against clinically-validated targets, including a PD-L1-targeting Probody therapeutic (CX-072), a PD-1-targeting Probody therapeutic (CX-188) and a CTLA-4-targeting Probody therapeutic (BMS-986249) being developed in collaboration with partnered with Bristol Myers Squibb.

The pipeline also includes first-in-class Probody-drug conjugates against highly attractive targets including a CD166-targeting Probody-drug conjugate wholly owned by CytomX (CX-2009), and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029).

CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody-drug conjugates due to their presence on many healthy tissues.

In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb and ImmunoGen, Inc.

PROCLAIM-072 Trial
In November 2018 CytomX presented clinical translational data from PROCLAIM-072, an ongoing Phase I/II, open-label, dose-finding trial evaluating CX-072, a Probody therapeutic targeting PD-L1, in a poster at the 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC) being held in Washington DC, USA.[1]

The PROCLAIM trial (Probody Clinical Assessment In Man) is an international umbrella program designed to evaluate CytomX’s Probody therapeutics. The first trial in this program, PROCLAIM-CX-072,  evaluates CX-072 as monotherapy and in combination with ipilimumab (Yervoy®; Bristol-Myers Squibb) or vemurafenib (Zelboraf®; Genentech/Roche ) in patients with metastatic or locally advanced unresectable solid tumors or lymphomas.

As part of the trial, participating patients received escalating doses of CX-072 from 0.3 mg/kg to 30 mg/kg. Biopsies were obtained from a subset of PROCLAIM-CX-072 patients during screening and at either 3-5 days after the first dose or after 4-6 weeks of CX-072 therapy. The presence of protease activity, CX-072 cleavage and activation, and measures of biological activity were assessed within tumors.

Results showed that protease activity was detected in the majority of patient biopsy samples (15 of 18 (83%)). Further, CX-072 was cleaved and activated within tumors, with the total amount of activated CX-072 increasing with dose. Doses of ≥ 3 mg/kg of CX-072 were estimated to achieve ≥ 98% PD-L1 target occupancy in patient tumors and attained concentrations that are associated with efficacy in a preclinical model. 7 of 12 evaluable patient biopsies showed an increase in tumor infiltration of CD8+ T cells, an activity consistent with the inhibition of the PD-1/PD-L1 signaling pathway.

“The preliminary data provide additional proof-of concept for the Probody platform and build upon the clinical data we have presented to date showing that CX-072 appears to be performing as designed in patients,” Kavanaugh noted

“These findings confirm that CX-072 is unmasked and activated and has biological activity in patient tumors while remaining predominantly masked and intact in circulation. This is another important step in understanding the full potential of our novel platform,” he concluded.

Reference
[1] PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas – NCT03013491 


Last Editorial Review: January 8, 2019

Featured Image: Life scientists researching in laboratory. Courtesy: © 2010 – 2019 Fotolia. Used with permission.

Copyright © 2019 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Share

Winding-Down of Research Operations but Astellas Retains Promising Antibody-Drug Conjugate R&D Programs

In a surprise move to most, but expected by industry insiders, Astellas Pharma, a Japan-based company focusing on the development of novel treatments in Urology, Oncology, Immunology, Nephrology and Neuroscience, announced this week that it is winding down its Agensys research operations in Santa Monica, California, USA.

The primary reason is that the company is to further refining its oncology strategy by expanding its investment in the research in new technologies and modalities and reducing its focus on Antibody-drug Conjugate (ADC) research.

The refined strategy became rather opivous when the company agreed to aquire Ganymed Pharmaceuticals for up to € 1.282 billion (about US $1.5 billion) in December 2016. The German based company focuses on developing a new class of cancer drugs called ideal monoclonal antibodies or IMABs for the treatment of solid cancers. One of these drugs, IMAB36, a first-in-class monoclonal antibody targeting the cell surface molecule Claudin18.2, has shown positive results in patients with advanced biomarker-positive gastric cancer reached all its endpoints.

“Agensys has positively contributed to Astellas’ objective of developing innovative treatments for patients with cancer,” said Wataru Uchida, Ph.D., senior vice president, Drug Discovery Research (DDR), Astellas.

Controversial
Ten years ago, in December 2007, Astellas announced it would buy the University of California, Los Angeles (UCLA) Spinout Agensys Benefit School for US $537 million. At that time the company announced the takeover it had paid US $387 million upfront to acquire Agensys, until 2001 known as UroGenesys, while Agensys’ shareholders would receive up to $150 million if certain business milestones are met.[1][2]

In 2007 ten-year-old Agensys focused on therapeutic antibody R&D and had identified 30 proprietary targets across 14 different types of cancer. Using the firm’s XenoMouse technology, licensed-in from Abgenix (now part of Amgen), the company was able to quickly generate fully human monoclonal antibodies. [1][2]

Ten years ago, the agreement also included Agensys’ GMP manufacturing facility, which produced antibodies for Phase I and early Phase II trials and the company’s lead product AGS-PSCA, an antibody that targets prostate stem cell antigen and is in Phase Ib.[3]

In 2007 Astellas had made some effort to boost its R&D capabilities in antibodies, having acquired a non-exclusive license to Regeneron’s VelocImmune technology as well as buying access  to a phage display library from Germany’s MorphoSys.

The company’s senior management expected Agensys to be the cornerstone of its biologics efforts.

However, the purchase of Agensys was a bit controversial and met with some opposition. Opponents worried about the fact that as a result of the purchase, a vast amount of public domain knowledge would be taken out of circulation.[1]

Valuable
The purchase of Agensys was also one of the most valuable university spin-offs acquired by Astellas. The deal  with UCLA was unique in that the school reportedly had some equity stake in the company. While the university never disclosed the actual financial terms of the deal, making it unclear how UCLA benefited from the transaction, it was abundantly clear that the biggest moneymakers in the deal included a small network of investors associated with the university. According to news reports published at the time, the university was short-changed while Agensys’ private investors were given a favorable deal because they were big donors of the university.[1]

Proof of concept
Uchida confirmed the benefits created by the Agensys team and tried to explain why the winding-down was a good option for Astellas and the company’s investors.

“The team has provided post-Proof of Concept compounds and antibody-related technology that have been incorporated into our promising oncology pipeline. Yet, the field of research has evolved and led to a new frontier of treatment options. Expanding our investment in this new area of research and development will be critically important and help us to better address high unmet medical needs, as well as deliver innovative benefits to patients in the fight against many types of cancers.”

The field of oncology is ever evolving, and Astellas believes that its research focus also needs to evolve in order to continue to be successful in developing potential therapies to help patients.  Astellas continuously evaluates its operations and investment programs to ensure it is optimizing its resources and research capabilities.

Continuing ADC Development
Astellas confirmed that it will continue certain clinical trials and collaborations on ADC programs that have been in progress at Agensys, including its collaboration with Seattle Genetics, Inc.

NCT02091999
Figure 1:0: Diagram of a study of escalating doses of ASG-22CE (ASG-22ME; enfortumab vedotin) given as monotherapy in subjects with metastatic urothelial cancer and other malignant solid tumors that express nectin-4 (NCT02091999). The purpose of this study is to evaluate the safety and pharmacokinetics ASG-22CE as well as assess the immunogenicity and antitumor activity in subjects with metastatic urothelial cancer and other malignant solid tumors.

While retaining key employees of its 220 employees at Agensys, Astellas plans to complete the wind-down of Agensys research operations in the first quarter of calendar 2018. The company is still reviewing the impact of this development on its financial forecasts for the fiscal year ending March 31, 2018.

Based on the latest available data, Agensys was sponsoring 6 clinical trials (5 have been recruiting patients while one is ongoing). In addition, 2 trails were terminated and 9 trials were completed.

Collaboration
Seattle Genetics and Agensys entered into the ADC collaboration in January 2007.  The companies expanded the collaboration in November 2009.

As part of the collaboration, Agensys has the right to obtain exclusive ADC licenses for multiple cancer targets. Seattle Genetics and Agensys further agreed are co-developing, globally co-commercialize and share profits on a 50:50 basis for ASG-5ME and ASG-22CE (ASG-22ME; enfortumab vedotin), while Seattle Genetics also had the option for 50:50 cost and profit-sharing of a third ADC program at the time of IND submission.


Last editorial review: July 27, 2017

Featured Image: Teamwork. Courtesy: © 2017. Fotolia. Used with permission.

Copyright © 2017 InPress Media Group, LLC. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Share

What to Expect at ASCO 2015?

The 51st ASCO – the Annual Meeting of the American Society of Clinical Oncology, which will take place in the McCormick Place Convention Center in Chicago, Illinois, May 29 – June 2, 2015 is expected attract more than 30,000 oncology professionals from around the world.

This year’s Annual Meeting will focus on the theme of Innovation and Illumination, pointing to the potential for integrating cancer science and health information technology (HIT) to achieve more rapid improvements in patient care. Along with new research, HIT initiatives such as ASCO’s CancerLinQ™ will be featured prominently at the meeting.

Sacituzumab Govitecan
Also prominently featured this years are the nearly 100 presentations and abstracts related to antibody-drug conjugates or ADCs. Among these presentations are two oral presentations featuring Immunomedics’ second generation antibody-drug conjugate (ADC) programs for solid cancer therapy. Leading that program is sacituzumab govitecan, an anti-TROP-2 antibody conjugated with SN-38, an active drug from irinotecan. Irinotecan is approved for the treatment of patients with colorectal cancer. Results from a Phase II study of sacituzumab govitecan in patients with advanced lung cancer will be updated in one of the 2 oral presentations. In addition to this oral presentation, results with sacituzumab govitecan in patients with late-stage triple-negative breast and gastrointestinal cancers will be reported in a Poster Discussion and a Poster Sessions, respectively.[1][2]

Labetuzumab Govitecan
Also presented, in the same Oral Abstract Session as sacituzumab govitecan, will be initial results from a Phase II study of labetuzumab govitecan, another SN-38-containing ADC, for patients with metastatic colorectal cancer. One of the presentation will feature a pilot study on TF2, a bispecific antibody, for pretargeted imaging of breast cancer. [3][4][5]

HuMax-TF-ADC and Daratumumab 
Genmab A/S announced that data on HuMax-TF-ADC, daratumumab, ofatumumab (Arzerra®; GSK) and HuMax-AXL-ADC will also be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.  This presentations include the first preliminary clinical data from the Phase I study of HuMax-TF-ADC in solid tumors and comprehensive data from the Phase II study of daratumumab in double refractory multiple myeloma. With the exception of the Phase II daratumumab data, which has been designated as a late breaking abstract by ASCO, the abstracts have been published at the ASCO website.

HuMax-TF-ADC Phase I Data
Preliminary safety and efficacy data from a Phase I dose escalation study of HuMax-TF-ADC to treat multiple solid tumors will be presented in a poster presentation. HuMax-TF-ADC is an antibody-drug conjugate (ADC) composed of a human antibody against tissue factor (TF) conjugated to Seattle Genetics’ clinically validated cytotoxic drug. HuMax-TF-ADC is being developed for the treatment of solid cancers. Based on its high expression on many solid tumors and its rapid internalization, TF is a suitable target for an ADC approach. Genmab is developing HuMax-TF-ADC using Seattle Genetics’ ADC technology under an agreement between the companies.

The data presented  includes data for 18 patients participating in this ongoing study. Preliminary data show a manageable safety profile with no dose limiting toxicities at doses of HuMax-TF-ADC of up to 1.8 mg/kg and preliminary evidence of anti-tumor efficacy was observed, including prolonged disease stabilization in an ovarian cancer patient (23 weeks), two castration resistant prostate cancer (CRPC) patients (18 and 36 weeks) and a confirmed partial response (PR) in a patient with cervical cancer. Data from further patients will be included in the poster at the time of the presentation including observed dose limiting toxicities in the 2.2 mg/kg cohort. Part 2 of the study is now be expanded from 30 to 80 patients, bringing the total patients in this study to approximately 110 patients.[6]

Daratumumab
Breaking abstracts and presentations also includes an update of daratumumab, a human CD38 monoclonal antibody with broad-spectrum killing activity. The trial drug, which is in clinical development for multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL), targets the CD38 molecule which is highly expressed on the surface of multiple myeloma cells. Daratumumab may also have potential in other cancers on which CD38 is expressed, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, plasma cell leukemia, acute myeloid leukemia, follicular lymphoma and mantle cell lymphoma. Daratumumab has been granted Breakthrough Therapy Designation from the US FDA. In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop and commercialize daratumumab.

During the annual ASCO meeting results from a number of studies will be presented, including results phase II study of daratumumab (DARA) monotherapy in patients with >=3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius, et al) (Late breaking abstract #LBA8512, Oral Presentation, Tuesday, June 2, 11:21AM to 11:33AM CDT), a twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux, et al) and 54767414MMY3004 (Castor) (Abstract #TPS8609, Poster session, Sunday/May 31, 8:00AM to 11:30AM CDT), A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus daratumumab (DARA) plus VMP in patients with previously untreated multiple myeloma (MM) who are ineligible for high-dose therapy: 54767414MMY3007 (Alcyone, et al.)(Abstract #TPS8608/Poster session, Sunday, May 31, 8:00AM to 11:30AM CDT), Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody (Abstract #8590/Poster session, Sunday, May 31, 8:00AM to 11:30AM CDT), Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT) – (Abstract #8587/Poster session, Sunday, May 31, 8:00AM to 11:30AM CDT)

Ofatumumab
Results of a phase III randomized, controlled study sponsored by Gilead Sciences, evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL)(Abstract #7023/Poster Session, Sunday, May 31, 8:00AM to 11:30AM) will be presented. Ofatumumab, which is marketed under a co-development and collaboration agreement between Genmab and Novartis, is a human monoclonal antibody that is designed to target the CD20 molecule found on the surface of chronic lymphocytic leukemia (CLL) cells and normal B lymphocytes. In the United States, ofatumumab is approved for use in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate. In the European Union, the drug is approved for use in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy. In more than 50 countries worldwide, ofatumumabis also indicated as monotherapy for the treatment of patients with CLL who are refractory after prior treatment with fludarabine and alemtuzumab.

HuMax-AXL-ADC
Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers (Abstract #3066, Poster session, Saturday, May 30, 8:00AM to 11:30AM). HuMax-AXL-ADC is an antibody-drug conjugate combining a high affinity human monoclonal antibody against AXL with one of Seattle Genetics’ clinically validated cytotoxic drug. AXL is a signaling molecule involved in multiple processes of tumor development and progression. The target molecule is highly expressed on a variety of solid cancers. Genmab is developing HuMax-AXL-ADC using Seattle Genetics’ ADC technology under a license agreement between the companies.

Mirvetuximab soravtansine
Clinical data presentations at upcoming ASCO annual meeting also include initial findings of ImmunoGen’s  mirvetuximab soravtansine (IMGN853) for ovarian cancer and results from the MARIANNE trial with ado-trastuzumab emtansine (Kadcyla®; Genentech/Roche). 

Mirvetuximab soravtansine is the first ADC to target folate receptor alpha (FRα), which is highly expressed on many ovarian cancers and on other types of solid tumors. The ASCO presentations will be on the initial findings from the Phase I expansion cohort assessing this ADC as a single agent for the treatment of patients with FRα-positive platinum-resistant ovarian cancer (abstract #5518) and the dose-finding results to date with a weekly dosing schedule compared with a once every three week schedule (abstract #5558).

Two years ago, ImmunoGen presented preliminary phase I results demonstrated for mirvetuximab soravtansine. These preliminary results showed encouraging signs in gynecologic tumors, including  2 partial responses. However, the preliminary data also showed dose limiting ocular toxicities at the higher doses.  Immunogen has, since then, been working on identifying a dosing regimen designed to minimizes ocular toxicity by decreasing early exposure levels.  Early results of these alternative dosing levels were presented in 2014, however, no efficacy data were disclosed at that time.

This year also expect updated results from the MARIANNE trial which focus on data evaluating three HER2-targeted regimens –  ado-trastuzumab emtansine plus pertuzumab (Perjeta®; Genentech/Roche), ado-trastuzumab emtansine alone, and trastuzumab (Herceptin®; Genentech/Roche) plus taxane chemotherapy – in people with previously untreated (first line) advanced HER2-positive breast cancer.

SGN-33A
Seattle Genetics’s SGN-33A (Anti-CD33) may enable the optimal targeting of CD33, which has been considered an attractive target for AML for over a decade based on efficacy observed with gemtuzumab ozogamicin (Mylotarg; Pfizer/Wyeth). Although gemtuzumab ozogamicin was withdrawn from the market in 2010, a  number of studies have shown a clear clinical benefit.

SGN-33A offers a novel DNA-binding payload (allowing higher potency relatively to currently used tubulin binders) and site-specific conjugation (offering a better safety profile).  Preliminary data presented at annual meeting of the American Society of Hematology (ASH) in San Francisco in December 2014 showed clear and dose-dependent activity with a relatively mild safety profile. Complete Response (CR) rates were 27% for the top three doses, with additional 50% of patients experiencing significant reductions in tumor burden. While this data was indeed  encouraging, industry experts consider it not (yet) sufficient to understand whether SGN-33A is effective enough to merit further development as mono therapy. Trial updates presented during the ASCO meeting are expected to shed more light in terms of durability of responses and long-term safety profile.

Partner programs
Both Seattle Genetics and ImmunoGen are expected to present multiple updates and new data related to their own programs as well as to their partnered programs. As indicated at the the 2015 PEGS meeting in Boston, Seattle Genetics is expected to have phase I data for its proprietary LIV1 program as well as news and updated news from multiple partnered programs including Pfizer’s anti-5T4 and anti-NOTCH3.

In total, multiple proprietary and collaborator antibody-drug conjugate (ADC) programs will be highlighted in more than 10 sessions at ASCO.  Data will be presented covering ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR) (AbbVie; Abstract #2510, poster presentation) as well as Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM) (AbbVie; Abstract #2016, poster presentation).  An additional presentation will cover STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC) (Genentech; Abstract #5029, poster presentation).

Among the ADC related presentations is also a a multivariate analysis of PFS from the AETHERA trial, a phase III study of brentuximab vedotin consolidation after autologous stem cell transplant for HL (Seattle Genetics; Abstract #8519, poster presentation) as well as a phase I trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children’s Oncology Group report (Investigator-sponsored; Abstract # 8544, poster presentation) will be presented on Monday, June 1, 2015.  Updated results of a phase II trial of brentuximab vedotin combined with RCHOP in frontline treatment of patients with high-intermediate/high-risk DLBCL (Seattle Genetics; Abstract #8506, oral presentation 11:21 a.m. CT) followed by Quality of life EQ-5D results from the AETHERA trial (Seattle Genetics; Abstract #6568, poster presentation) and brentuximab vedotin plus AVD for non-bulky limited stage classical Hodgkin lymphoma: a phase II trial (Investigator-sponsored; Abstract #8505, oral presentation 11:09 a.m. CT)
Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses and lower dose level (Genentech; Abstract #8503, oral presentation 9:45 a.m. – 12:45 p.m. CT).  Finally, data will be presented from a phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RCC) (Agensys; Abstract #2503, oral presentation 8:00 – 11:00 a.m. CT).

Immunogen
At this time, industry experts consider Immunogen’s partnered pipeline slighltly less advanced than the Seattle Genetics program. One reason is that ImmunoGen’s program (unfortunately) to a great degree relies on the (pre-) clinical programs of Novartis  and Lilly. Novartis started phase I with for LOP628 (anti-cKIT) in January 2015, their study is currently listed as suspended.

More than 90 abstracts
This years, more than 90 abstracts and presentations include updates and (late breaking) news covering clinical studies involving Antibody-drug conjugates.

One of the featured educational sessions is on Monday, June 1. As part of the “Developmental Therapeutics and Translational Research; Breast Cancer” Track, Francisco J. Esteva, MD, PhD
(NYU Langone Medical Center), Kathy Miller, MD (Indiana University Melvin and Bren Simon Cancer Center) and Beverly A. Teicher, PhD (Chair; National Cancer Institute at the National Institutes of Health) will be leading “Antibody-Drug Conjugates: New Horizons to Maximize Efficacy and Minimize Toxicity.”

While our team has reviewed just a few interesting antibody-drug conjugates, there are many other ADCs which entered the clinical testing phase in 2013-2014.  Some of these trials, as shown, are expected to generate interesting preliminary phase I data to be presented at this years ASCO meeting, making this year’s meeting one of the most interesting society meetings covering antibody-drug conjugates.


Last editorial update: May 26, 2015

Photo: The AACR 2015 Annual Meeting. More than 18,000 physicians, researchers, health care professionals, cancer survivors and patient advocates attended the annual meeting at the Pennsylvania Convention Center highlighting the latest findings in all major areas of cancer research from basic through clinical and epidemiological studies. Photo courtesey: ©AACR/Phil McCarten 2015.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Skip to toolbar